<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04034134</url>
  </required_header>
  <id_info>
    <org_study_id>ZGJAK003</org_study_id>
    <nct_id>NCT04034134</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata</brief_title>
  <official_title>A Phase Ⅱ Study to Evaluate the Safety and Efficacy of Jaktinib Hydrochloride Tablets in the Treatment of Severe Alopecia Areata.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Suzhou Zelgen Biopharmaceuticals Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was an open-label, Multi-center, randomized phase Ⅱ study. Patients with severe Alopecia&#xD;
      Areata were randomized to receive 50mg bid, 150mg qd or 200 mg qd of oral Jaktinib&#xD;
      Hydrochloride Tablets.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2019</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effective rate</measure>
    <time_frame>From randomization of the first subject until the last subject complete 6 months treatment</time_frame>
    <description>Effective rate = (cure + obvious effect + effective)/total cases *100%;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SALT score change</measure>
    <time_frame>From randomization of the first subject until the last subject complete 6 months treatment</time_frame>
    <description>Score and take photos (4 areas on the head), taking photos in the same position and light condition each time;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (AASIS)</measure>
    <time_frame>From randomization of the first subject until the last subject complete 6 months treatment</time_frame>
    <description>AASIS was used to score the quality of life of the subjects</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety variables will be summarized using descriptive statistics based on adverse events collection</measure>
    <time_frame>From randomization of the first subject until the last subject complete 6 months treatment</time_frame>
    <description>Patients with adverse events/all patients *100%</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>Jaktinib Hydrochloride Tablets 50mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Jaktinib Hydrochloride Tablets 150mg qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Jaktinib Hydrochloride Tablets 200mg qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jaktinib Hydrochloride Tablets</intervention_name>
    <description>50 mg twice-daily (BID)</description>
    <arm_group_label>Jaktinib Hydrochloride Tablets 50mg bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jaktinib Hydrochloride Tablets</intervention_name>
    <description>150 mg quaque die (QD)</description>
    <arm_group_label>Jaktinib Hydrochloride Tablets 150mg qd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jaktinib Hydrochloride Tablets</intervention_name>
    <description>200 mg quaque die (QD)</description>
    <arm_group_label>Jaktinib Hydrochloride Tablets 200mg qd</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years age or older ,male or female；&#xD;
&#xD;
          -  Alopecia areata diagnosed clinically；&#xD;
&#xD;
          -  Patients with alopecia accounting for 50% or more of the total scalp area and stable&#xD;
             for at least 6 months or more；&#xD;
&#xD;
          -  Patients can complete treatment for at least six months；&#xD;
&#xD;
          -  Requirements for pregnant or lactating female and male and female of childbearing&#xD;
             age；Female patients must be satisfied：Menopause (defined as no menstruation for at&#xD;
             least one year);Or have been surgically sterilized；Or have fertility, but must&#xD;
             satisfy：Pregnancy tests conducted within 7 days before randomization must be&#xD;
             negative；And agree to use appropriate contraceptive methods throughout the trial&#xD;
             period, including at least one barrier method；And no breastfeeding；Male patients must&#xD;
             agree to use appropriate contraceptive measures throughout the trial, including at&#xD;
             least one barrier method；&#xD;
&#xD;
          -  Patients are voluntarily enrolled in the Study and can be treated and visited&#xD;
             according to the requirements of the protocol after signing the Informed Consent Form；&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alopecia caused by syphilitic alopecia, thyroid disease, trichotilomania, head moss,&#xD;
             connective tissue disease, infection, zinc deficiency and iron deficiency;&#xD;
&#xD;
          -  Patients with acute diffuse alopecia areata (ADTAFS)&#xD;
&#xD;
          -  Patients with active tuberculosis&#xD;
&#xD;
          -  The following diseases were combined within 6 months before randomization:thyroid&#xD;
             diseases ，liver diseases, malnutrition, heart diseases, nervous system diseases,&#xD;
             gastrointestinal disorders, tumors and psychiatric diseases&#xD;
&#xD;
          -  HIV positive, active hepatitis B virus positive (HBsAg or HBeAg positive) and HCV-RNA&#xD;
             positive at screening；&#xD;
&#xD;
          -  Other patients with abnormal history or clinical manifestations that may affect&#xD;
             participants participation in the study or may confuse the results of the study；&#xD;
&#xD;
          -  Within two weeks before randomization，Patients who received glucocorticoid topical&#xD;
             therapy, anthracene ointment, minoxidil, SADBE/DPCP contact immunotherapy,&#xD;
             photochemotherapy or cryotherapy；&#xD;
&#xD;
          -  Before randomization，oral or injected any medicines to treat hair loss (including the&#xD;
             glucocorticoids was detected in injection, systemic corticosteroids, antihistamines,&#xD;
             stephania drugs, glycyrrhizin, glycine, methionine compound tablet, compound&#xD;
             glycyrrhizin glucoside) and other liquorice extract, ring spore element, anti TNF&#xD;
             antibody, IFN - gamma, IL - 2 antibodies, for alopecia areata therapy of traditional&#xD;
             Chinese medicine and other JAK inhibitor) and washout period less than seven half-life&#xD;
             of patients;&#xD;
&#xD;
          -  Participants in a clinical trial of any drug or medical device within 4 weeks prior to&#xD;
             randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>qianjin Lu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>qianjin Lu, MD</last_name>
    <phone>13787097676</phone>
    <email>qianlu5860@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>siqi Fu, MD</last_name>
    <phone>18874139898</phone>
    <email>18874139898@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chongqing Chinese Traditional Medicine Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guofu Yan, Doctor</last_name>
      <phone>13983657860</phone>
      <email>yanguofucq@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The second xaingya hospital of central south university</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>qianjin Lu, MD</last_name>
      <phone>13787097676</phone>
      <email>qianlu5860@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>siqi Fu, MD</last_name>
      <phone>18874139898</phone>
      <email>18874139898@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

